JP2005536453A - 部分的なペプチド擬似物及び方法 - Google Patents

部分的なペプチド擬似物及び方法 Download PDF

Info

Publication number
JP2005536453A
JP2005536453A JP2003569658A JP2003569658A JP2005536453A JP 2005536453 A JP2005536453 A JP 2005536453A JP 2003569658 A JP2003569658 A JP 2003569658A JP 2003569658 A JP2003569658 A JP 2003569658A JP 2005536453 A JP2005536453 A JP 2005536453A
Authority
JP
Japan
Prior art keywords
seq
cell
amino acid
partial peptide
peptide mimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003569658A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536453A5 (enExample
Inventor
エイチ． メイヨ，ケビン
アール． ホイ，トーマス
カロリー フレーダー，ラビー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota Twin Cities
Original Assignee
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota System filed Critical University of Minnesota System
Publication of JP2005536453A publication Critical patent/JP2005536453A/ja
Publication of JP2005536453A5 publication Critical patent/JP2005536453A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2003569658A 2002-02-20 2003-02-20 部分的なペプチド擬似物及び方法 Pending JP2005536453A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35927202P 2002-02-20 2002-02-20
PCT/US2003/005106 WO2003070751A2 (en) 2002-02-20 2003-02-20 Partial peptide mimetics and methods

Publications (2)

Publication Number Publication Date
JP2005536453A true JP2005536453A (ja) 2005-12-02
JP2005536453A5 JP2005536453A5 (enExample) 2006-04-06

Family

ID=27757772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003569658A Pending JP2005536453A (ja) 2002-02-20 2003-02-20 部分的なペプチド擬似物及び方法

Country Status (6)

Country Link
US (2) US7056514B2 (enExample)
EP (1) EP1572719A4 (enExample)
JP (1) JP2005536453A (enExample)
AU (1) AU2003211163A1 (enExample)
CA (1) CA2476427A1 (enExample)
WO (1) WO2003070751A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486125B1 (en) * 1996-05-24 2002-11-26 Regents Of The University Of Minnesota Synthesis of soluble β-sheet forming peptides
WO2003070751A2 (en) * 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
JP2007512234A (ja) * 2003-10-17 2007-05-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療活性を有する修飾ポリペプチド及びその使用方法
US7493333B2 (en) 2004-09-03 2009-02-17 Biowisdom Limited System and method for parsing and/or exporting data from one or more multi-relational ontologies
US7496593B2 (en) 2004-09-03 2009-02-24 Biowisdom Limited Creating a multi-relational ontology having a predetermined structure
US7505989B2 (en) 2004-09-03 2009-03-17 Biowisdom Limited System and method for creating customized ontologies
US20060053172A1 (en) * 2004-09-03 2006-03-09 Biowisdom Limited System and method for creating, editing, and using multi-relational ontologies
CA2867023A1 (en) 2004-10-04 2006-04-20 Kevin H. Mayo Calixarene-based peptide conformation mimetics, methods of use, and methods of making
JP2010519338A (ja) * 2007-03-01 2010-06-03 マリンクロット インコーポレイテッド 組込み型光活性ペプチドおよびその使用
EP2131861A2 (en) * 2007-03-01 2009-12-16 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
EP2178849A1 (en) * 2007-07-31 2010-04-28 Mallinckrodt Inc. Integrated photoactive agents and uses thereof
US20210138080A1 (en) 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0652230B1 (en) 1987-08-11 2005-12-14 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5171739A (en) 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
WO1994025476A1 (en) 1993-04-30 1994-11-10 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5334584A (en) 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5089274A (en) 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5595887A (en) 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
CA2095861C (en) 1990-11-28 2002-06-11 Ronald H. Hoess Structural proteins from artificial genes
AU9127591A (en) 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5190873A (en) 1991-06-21 1993-03-02 California Institute Of Biological Research Hybrid tryptophan aporepressor containing ligand binding sites
WO1993023434A2 (en) 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
EP0675127A1 (en) 1992-12-28 1995-10-04 Nippon Shinyaku Company, Limited Quinolinecarboxylic acid derivative and process for producing the same
WO1994017819A1 (en) 1993-02-02 1994-08-18 Xoma Corporation Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5348942A (en) 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
AU694108B2 (en) 1993-03-12 1998-07-16 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
AU7175694A (en) 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
DE69431922T2 (de) 1993-07-02 2003-11-13 Incyte Pharmaceuticals, Inc. Glycosilierte und nichtglycolisierte bakterizide/die permeabilität erhoehende proteine und methoden zu ihrer herstellung
WO1995002414A1 (en) 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
GB9506806D0 (en) 1995-04-01 1995-05-24 Univ Leeds Improvements relating to polymers
WO1996037212A1 (en) 1995-05-26 1996-11-28 Torrey Pines Institute For Molecular Studies POLYPEPTIDE COMPOUNDS THAT FORM β SHEETS
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6486125B1 (en) * 1996-05-24 2002-11-26 Regents Of The University Of Minnesota Synthesis of soluble β-sheet forming peptides
US5955577A (en) * 1996-06-27 1999-09-21 Regents Of The University Of Minnesota Method for synthesizing a water-soluble β-sheet forming peptide
AU2001231016A1 (en) 2000-01-20 2001-07-31 Regents Of The University Of Minnesota Peptides with antibacterial activity
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
JP2007512234A (ja) 2003-10-17 2007-05-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療活性を有する修飾ポリペプチド及びその使用方法
ITPD20040171A1 (it) 2004-06-29 2004-09-29 Maus Spa Dispositivo per il bloccaggio di pezzi soggetti a lavorazioni meccaniche e macchina utensile includente detto dispositivo
CA2867023A1 (en) 2004-10-04 2006-04-20 Kevin H. Mayo Calixarene-based peptide conformation mimetics, methods of use, and methods of making
US20070010438A1 (en) * 2005-07-08 2007-01-11 Mayo Kevin H Tumor treatment using beta-sheet peptides and radiotherapy

Also Published As

Publication number Publication date
EP1572719A4 (en) 2007-11-14
US20060128629A1 (en) 2006-06-15
US20040053828A1 (en) 2004-03-18
EP1572719A2 (en) 2005-09-14
WO2003070751A3 (en) 2007-04-05
WO2003070751A2 (en) 2003-08-28
CA2476427A1 (en) 2003-08-28
US7056514B2 (en) 2006-06-06
US7339023B2 (en) 2008-03-04
AU2003211163A1 (en) 2003-09-09
AU2003211163A8 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
JP7166933B2 (ja) プログラム細胞死を誘導するｃｄ４７のアゴニスト剤及びプログラム細胞死の欠陥と関連する疾患の治療におけるそれらの使用
RU2683649C1 (ru) Композиция для лечения и профилактики доброкачественной гиперплазии простаты
CA2650113C (en) Compositions for treatment of cancer
Mayo et al. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity
JP2005536453A (ja) 部分的なペプチド擬似物及び方法
Xue et al. A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis
CN106188271B (zh) 细胞凋亡抑制剂及其用途
US20030130484A1 (en) Inhibitors and disassemblers of fibrillogenesis
WO1999013899A1 (en) Peptides and peptidomimetics for inhibiting complement activation
US7208475B2 (en) Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US7144982B2 (en) Polypeptides with therapeutic activity and methods of use
AU2017225015A1 (en) Medical Use
US7408028B2 (en) Peptides, antibodies thereto, and their use in treatment of central nervous system, damage
AU2003253341C1 (en) Method for isolating an intestinal cholesterol binding protein
CN109593123A (zh) 一种衍生自rps23rg1的多肽及其应用
EP2234632B1 (en) Proteinaceous compounds
BR112021003812A2 (pt) terapias peptídicas para o tratamento de câncer e usos das mesmas
Mele et al. UPARANT: A Urokinase Receptor–Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and
CA2642494A1 (en) Novel phosphopeptides and uses thereof in preventing kidney stone formation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090915